A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia

Trial Profile

A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2010

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 24 Aug 2010 Results published in the Journal of Clinical Psychiatry.
    • 30 Apr 2009 Results presented at the 61st Annual Meeting of the American Academy of Neurology (AAN 2009).
    • 04 Feb 2008 Status changed from in progress to completed. Updated from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top